A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients

European Journal of Cancer

Volumn 47, Issue 10, 2011, Pages 1498-1503

  Mao, Lili ^a   Si, Lu ^a   Chi, Zhihong ^a   Cui, Chuanliang ^a   Sheng, Xinan ^a   Li, Siming ^a   Tang, Bixia ^a   Guo, Jun ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Acral melanoma; Dose intensity; Duration; High dose interferon 2b; Toxicity

Indexed keywords

ALPHA2B INTERFERON;

ADULT; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG MEGADOSE; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-ALPHA; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; RECURRENCE; RISK; TIME FACTORS; TREATMENT OUTCOME;

EID: 79958797459     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.03.019     Document Type: Article

References (28)

1. A. Hauschild Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations? Curr Oncol 16 2009 3 6
2. A.M. Eggermont, and M. Gore Randomized adjuvant therapy trials in melanoma: surgical and systemic Semin Oncol 34 2007 509 515 (Pubitemid 350245676)
3. A.A. Tarhini, and J.M. Kirkwood Clinical and immunologic basis of interferon therapy in melanoma Ann N Y Acad Sci 1182 2009 47 57
4. T. Kato, T. Suetake, N. Tabata, K. Takahashi, and H. Tagami Epidemiology and prognosis of plantar melanoma in 62 Japanese patients over a 28-year period Int J Dermatol 38 1999 515 519 (Pubitemid 29331928)
5. R.J. Collins Melanoma in the Chinese of Hong Kong. Emphasis on volar and subungual sites Cancer 54 1984 1482 1488 (Pubitemid 14003559)
6. C.F. Bellows, P. Belafsky, I.S. Fortgang, and D.J. Beech Melanoma in African-Americans: trends in biological behavior and clinical characteristics over two decades J Surg Oncol 78 2001 10 16
7. K. Ishihara, T. Saida, and A. Yamamoto Updated statistical data for malignant melanoma in Japan Int J Clin Oncol 6 2001 109 116 (Pubitemid 32634488)
8. T. Matsumoto, S. Shibata, and S. Yasue Interval sentinel lymph nodes in patients with cutaneous melanoma: A single-institution study in Japan J Dermatol 37 2010 629 634
9. M. Roh, J. Kim, and K. Chung Treatment and outcomes of melanoma in acral location in Korean patients Yonsei Med J 51 2010 562 568
10. Y.J. Chen, C.Y. Wu, and J.T. Chen Clinicopathologic analysis of malignant melanoma in Taiwan J Am Acad Dermatol 41 1999 945 949
11. N.M. Luk, L.C. Ho, and C.L. Choi Clinicopathological features and prognostic factors of cutaneous melanoma among Hong Kong Chinese Clin Exp Dermatol 29 2004 600 604 (Pubitemid 39573644)
12. J. Rex, C. Paradelo, and C. Mangas Management of primary cutaneous melanoma of the hands and feet: A clinicoprognostic study Dermatol Surg 35 2009 1505 1513
13. R.F. Kefford Adjuvant therapy of cutaneous melanoma: the interferon debate Ann Oncol 14 2003 358 365 (Pubitemid 36367410)
14. J.M. Kirkwood, M.H. Strawderman, and M.S. Ernstoff Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 1996 7 17 (Pubitemid 26019991)
15. K. Wheatley, N. Ives, and B. Hancock Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials Cancer Treat Rev 29 2003 241 252 (Pubitemid 37069655)
16. D. Pectasides, U. Dafni, and D. Bafaloukos Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma J Clin Oncol 27 2009 939 944
17. H. Gogas, D. Bafaloukos, and J. Ioannovich Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year-a Hellenic Cooperative Oncology Group study Anticancer Res 24 2004 1947 1952 (Pubitemid 38954615)
18. C.M. Balch, A.C. Buzaid, and S.J. Soong Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma J Clin Oncol 19 2001 3635 3648 (Pubitemid 32786276)
19. J.M. Kirkwood, J.G. Ibrahim, and V.K. Sondak High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 J Clin Oncol 18 2000 2444 2458 (Pubitemid 30415832)
20. J.M. Kirkwood, J.G. Ibrahim, and J.A. Sosman High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801 J Clin Oncol 19 2001 2370 2380 (Pubitemid 32391207)
21. J.M. Kirkwood, J. Ibrahim, and D.H. Lawson High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696 J Clin Oncol 19 2001 1430 1436 (Pubitemid 32202550)
22. P.A. Ascierto, M. Napolitano, and E. Celentano Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-a 2b treatment J Transl Med 8 2010 76
23. E. Lakatos Sample sizes based on the log-rank statistic in complex clinical trials Biometrics 44 1988 229 241 (Pubitemid 18098824)
24. E. Lakatos Designing complex group sequential survival trials Stat Med 21 2002 1969 1989 (Pubitemid 34752618)
25. P.T. Bradford, A.M. Goldstein, M.L. McMaster, and M.A. Tucker Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005 Arch Dermatol 145 2009 427 434
26. A.M. Eggermont, S. Suciu, and M. Santinami Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial Lancet 372 2008 117 126 (Pubitemid 351952257)
27. K.M. McMasters, M.J. Edwards, and M.I. Ross Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma Ann Surg 252 2010 460 466
28. Eggermont AM, Suciu S, Testori A, et al. Ulceration of primary melanoma and responsiveness to adjuvant interferon therapy: analysis of the adjuvant trials EORTC18952 and EORTC18991 in 2644 patients. J Clin Oncol 2009;27:Abstr9007.